Multi-kinase-IN-7 

Multi-kinase-IN-7 is a multikinase inhibitor with IC₅₀s of 2.19, 2.95, 3.59 and 9.31 μM against EGFR, VEGFR2, TrKA and CDK2, respectively. Multi-kinase-IN-7 shows moderate and weaker activity against FAK, AKT1, GSK3β and CDK5 with IC₅₀ values of 6.3, 9.2, 11.7 and 23.4 μM, respectively. Multi-kinase-IN-7 displays broad spectrum anti­proliferative potential against NCI cancer cell lines. Multi-kinase-IN-7 induces cell cycle arrest, apoptosis and necrosis. Multi-kinase-IN-7 Inhibitor can be used for the study of breast cancer^[1].

Multi-kinase-IN-7 (Compound 12b) (0.01-100 μM, 24 h) displays broad spectrum anti proliferative potential against NCI cancer cell lines with GI₅₀ mean value of 10.63 μM and exhibits potent anti­proliferative activities against all breast cancer lines with GI₅₀ ranges of 4.03-15.3 μM^[1].
Multi-kinase-IN-7 (15.3 μM, 48 h) arrests the cell cycle of MDA-MB-231 cells at the G2/M phase and significantly induces apoptosis (through intrinsic pathway) and necrosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

393.24

C₁₈H₁₃BrN₆

N#CC1=C(N)N2C(NC1C3=CC=C(Br)C=C3)=NC(C4=CC=CC=C4)=N2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Eldeeb AH, et al. Design, synthesis and biological evaluation of triazolo[1,5-a]pyrimidine derivatives as new antiproliferative agents with multikinase inhibitory activity. Bioorg Chem. 2025 Aug 22;165:108899.  [Content Brief]